| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952, 2018 | 2239 | 2018 |
| A placebo-controlled trial of obeticholic acid in primary biliary cholangitis F Nevens, P Andreone, G Mazzella, SI Strasser, C Bowlus, P Invernizzi, ... New England Journal of Medicine 375 (7), 631-643, 2016 | 1152 | 2016 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1129 | 2019 |
| Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection M Bourlière, SC Gordon, SL Flamm, CL Cooper, A Ramji, M Tong, ... New England Journal of Medicine 376 (22), 2134-2146, 2017 | 670 | 2017 |
| Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial EK Geissler, AA Schnitzbauer, C Zülke, PE Lamby, A Proneth, C Duvoux, ... Transplantation 100 (1), 116-125, 2016 | 468 | 2016 |
| Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B P Marcellin, SH Ahn, X Ma, FA Caruntu, WY Tak, M Elkashab, WL Chuang, ... Gastroenterology 150 (1), 134-144. e10, 2016 | 399 | 2016 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 371 | 2020 |
| Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation D Verran, T Kusyk, D Painter, J Fisher, D Koorey, S Strasser, G Stewart, ... Liver Transplantation 9 (5), 500-505, 2003 | 325 | 2003 |
| Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation EJ Gane, PW Angus, S Strasser, DHG Crawford, J Ring, GP Jeffrey, ... Gastroenterology 132 (3), 931-937, 2007 | 321 | 2007 |
| Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial R Pinyol, R Montal, L Bassaganyas, D Sia, T Takayama, GY Chau, ... Gut 68 (6), 1065-1075, 2019 | 246 | 2019 |
| Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B SJ Patterson, J George, SI Strasser, AU Lee, W Sievert, AJ Nicoll, ... Gut 60 (2), 247-254, 2011 | 236 | 2011 |
| Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10‐year follow‐up SI Strasser, D Myerson, CL Spurgeon, KM Sullivan, B Storer, HG Schoch, ... Hepatology 29 (6), 1893-1899, 1999 | 218 | 1999 |
| Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH R Loomba, M Noureddin, KV Kowdley, A Kohli, A Sheikh, G Neff, ... Hepatology 73 (2), 625-643, 2021 | 209 | 2021 |
| A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for … AA Schnitzbauer, C Zuelke, C Graeb, J Rochon, I Bilbao, P Burra, ... BMC cancer 10, 1-8, 2010 | 191 | 2010 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 190 | 2022 |
| Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index EL de Graaf, J Kench, P Dilworth, NA Shackel, SI Strasser, D Joseph, ... Journal of gastroenterology and hepatology 27 (3), 540-546, 2012 | 188 | 2012 |
| A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis PW Angus, SJ Patterson, SI Strasser, GW McCaughan, E Gane Hepatology 48 (5), 1460-1466, 2008 | 187 | 2008 |
| Cirrhosis of the liver in long-term marrow transplant survivors SI Strasser, KM Sullivan, D Myerson, CL Spurgeon, B Storer, HG Schoch, ... Blood, The Journal of the American Society of Hematology 93 (10), 3259-3266, 1999 | 179 | 1999 |
| High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis M Puoti, GR Foster, S Wang, D Mutimer, E Gane, C Moreno, TT Chang, ... Journal of hepatology 69 (2), 293-300, 2018 | 177 | 2018 |
| Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management SI Strasser, GB McDonald Blood, The Journal of the American Society of Hematology 93 (4), 1127-1136, 1999 | 172 | 1999 |
